Spots Global Cancer Trial Database for Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors
Official Title: A Multicenter, Retrospective, Medical Record Review Of The Effectiveness Of Lanreotide Following Treatment With Octreotide In Patients With Neuroendocrine Tumors
Study ID: NCT03112694
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to understand how people with neuroendocrine tumors respond to treatment with lanreotide after having received treatment with octreotide.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Moffitt Cancer Center, Tampa, Florida, United States
Cancer Center of Kansas, Wichita, Kansas, United States
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
Mercy Medical Center, Baltimore, Maryland, United States
Tufts Medical Center, Boston, Massachusetts, United States
Mayo Clinic, Rochester, Minnesota, United States
National Transitional Research, East Setauket, New York, United States
Allegheny Cancer Center, Pittsburgh, Pennsylvania, United States
Contact Details
Name: Ipsen Medical Director
Affiliation: Ipsen
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
